Skip to main content

Table 1 Clinical and demographic characteristics of the flurbiprofen and control (tramadol) groups

From: Intravenous flurbiprofen for post-thymectomy pain relief in patients with myasthenia gravis

Characteristic

Flurbiprofen

Control (tramadol)

p value*

n

110

90

Ā 

Male/female, n (%)

59 (53.6)/51 (46.4)

43 (47.8)/47 (52.2)

0.504

Age at surgery, years

31.1ā€‰Ā±ā€‰11.8

30.3ā€‰Ā±ā€‰13.1

0.691

Mean disease duration, years

1.5ā€‰Ā±ā€‰0.8

1.8ā€‰Ā±ā€‰0.9

0.401

With/without medulla symptoms, n (%)

17 (15.5)/93 (84.5)

15 (16.7)/75 (83.3)

0.816

MGFA stage, n (%)

Ā Ā 

0.954

I

46 (41.8)

38 (42.2)

Ā 

IIa

41 (37.3)

33 (36.7)

Ā 

IIb

17 (15.5)

15 (16.7)

Ā 

IIIa

6 (5.45)

4 (4.44)

Ā 

Time of operation (min)

111.8ā€‰Ā±ā€‰25.4

116.4ā€‰Ā±ā€‰24.0

0.843

Time of chest drainage (d)

2.7ā€‰Ā±ā€‰0.5

2.4ā€‰Ā±ā€‰0.8

0.927

Myasthenia crisis

4 (3.6)

3 (3.3)

0.911

MGFA stage at 72 h after operation, n (%)

Ā Ā 

0.931

I

47 (42.7)

39 (43.3)

Ā 

IIa

42 (38.2)

33 (36.7)

Ā 

IIb

15 (13.6)

14 (15.6)

Ā 

IIIa

6 (5.45)

4 (4.44)

Ā 

Adverse reactions

Ā Ā Ā 

Nausea and vomiting

14 (12.7)

26 (28.9)

0.021

Headache

5 (4.5)

9 (10.0)

0.162

Facial flushing

3 (2.7)

4 (4.4)

0.526

  1. Values are given as medianā€‰Ā±ā€‰SD or (percentage). MGFA, Myasthenia Gravis Foundation Association.
  2. * p-values were calculated by the Ļ‡ 2 test.